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Dexmethylphenidate: A Viewpoint 
L. Eugene Arnold, Ohio State University, Columbus, Ohio, USA 
For a century it has been known that some drugs and naturally occurring physiological 
molecules (e.g. hexose, amino acids) occur in stereoisomers, with a right- and left-hand 
orientation. Some of these, in solution, have the property of deflecting light to the right or left 
and are also called optical isomers, designated as dextro- and levo- isomers. Not all 
stereoisomers are optical. Other types of stereoisomers include erythro- versus threo- and cis 
versus trans. Most naturally occurring molecules are all one isomer (e.g. all levo). But synthetic 
molecules (drugs) are made in approximately equal proportions of each isomer and require 
separation if only one isomer is desired. 
It has also been known for decades that there are subtle differences between drug isomers 
in action. This offers the possibility of ‘chiral pharmacology’. As early as the 1930s 
amphetamine was available as the racemic mixture, marketed as Benzedrine®i and as the dextro- 
isomer, marketed as Dexedrine®. The levo- isomer was briefly marketed as Cydril®. Recently 
there has been an upsurge of interest in the possibilities of chiral pharmacology, driven partly by 
commercial incentive for patentable products as patents expire on racemic drugs. This interest 
has resulted in several contributions to the range of pharmacological options. 
Dexmethylphenidate is one of those. 
Methylphenidate actually has four isomers: dextro- and levo- crossed with erythro- and 
threo-. Erythromethylphenidate was never marketed. Threomethylphenidate was marketed for 40 
years as Ritalin®. Only in the past decade or so was the technology developed for economically 
separating out dextro-threo-methylphenidate, or dexmethylphenidate, in commercial quantities. 
The relationship of dexmethylphenidate to levomethylphenidate appears to be somewhat 
different from the relationship of dextroamphetamine to levoamphetamine. In a series of 
experiments in children and naturally hyperkinetic dogs in the early 1970s, we found that both 
amphetamine isomers were significantly better than placebo for attention deficit hyperactivity 
disorder (known as minimal brain dysfunction at that time) and not significantly different from 
each other. Despite the similarity in behavioural effect, there were some subtle differences. 
Dextroamphetamine but not levoamphetamine improved visual-motor performance on the 
Bender Gestalt Test significantly more than did placebo. There was a nonsignificant tendency for 
the levo- isomer to have a slower start and to build up effect over several days or weeks. 
Affective adverse effects seemed anecdotally less severe with the levo- isomer, with some 
parents commenting that the child seemed more spontaneous and natural than with the ‘other’ 
isomer (in a crossover design) even though behaviour was as good with either. Blindly judged 
clinical results were better for more children with dextroamphetamine, but some children had 
their best result from levoamphetamine, and a couple responded to levoamphetamine who did 
not respond satisfactorily to any other available stimulant. 
In contrast to the amphetamine situation, dexmethylphenidate appears to ‘have all the 
action’, with levomethylphenidate not significantly better than placebo, and with similar results 
from equimolar dexmethylphenidate and racemic methylphenidate, which implies that 
levomethylphenidate does nothing or little. This difference may arise from the fact that 
methylphenidate, in contrast to amphetamine, is mainly metabolised in the liver rather than being 
renally excreted as the parent compound. In any event, it appears in this preliminary view of the 
data that the development of dexmethylphenidate from racemic threo-methylphenidate may be a 
more important therapeutic contribution than the development of dextroamphetamine from 
racemic amphetamine. Now if it were just available in an extended-release preparation . . . 
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